Predicting the probability of significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: Development of a novel pre-biopsy nomogram: Original article

International Journal of Urology

Volumn 17, Issue 3, 2010, Pages 274-280

  Ohigashi, Takashi ^a   Kanao, Kent ^c   Mizuno, Ryuichi ^b   Kikuchi, Eiji ^b   Nakashima, June ^b   Oya, Mototsugu ^b  

^a International University of Health and Welfare Mita Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

Author keywords

Diagnosis; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NOMOGRAM; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; TUMOR VOLUME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 77749285724     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02453.x     Document Type: Article

References (29)

1. Cheng L, Koch MO, Juliar BE et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J. Clin. Oncol. 2005 23 : 2911 2917.
2. Cheng L, Bergstralh EJ, Cheville JC et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 1998 22 : 1491 1500.
3. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986 1 : 60 3.
4. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J. Urol. 1998 160 : 2407 2411.
5. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996 275 : 288 294.
6. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 374.
7. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994 44 : 862 867.
8. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J. Urol. 1995 153 : 1543 1548.
9. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J. Urol. 1996 156 : 1059 1063.
10. Augustin H, Hammerer PG, Graefen M et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur. Urol. 2003 43 : 455 460.
11. Patel DA, Presti JC Jr., McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J. Clin. Oncol. 2005 23 : 6157 6162.
12. Aus G, Bergdahl S, Hugosson J, Norlen L. Volume determinations of the whole prostate and of adenomas by transrectal ultrasound in patients with clinically benign prostatic hyperplasia: correlation of resected weight, blood loss and duration of operation. Br. J. Urol. 1994 73 : 659 663.
13. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 2002 167 : 528 534.
14. Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer 1995 75 : 530 538.
15. Scales CD Jr., Presti JC Jr., Kane CJ et al. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy - results from the SEARCH database. J. Urol. 2007 178 : 1249 1252.
16. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004 64 : 544 550.
17. Thorson P, Vollmer RT, Arcangeli C, Keetch DW, Humphrey PA. Minimal carcinoma in prostate needle biopsy specimens: diagnostic features and radical prostatectomy follow-up. Mod. Pathol. 1998 11 : 543 551.
18. Ravery V, Szabo J, Toublanc M et al. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br. J. Urol. 1996 77 : 724 728.
19. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J. Urol. 2003 170 : 1792 1797.
20. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J. Urol. 2007 177 : 107 112.
21. Dong F, Kattan MW, Steyerberg EW et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J. Urol. 2008 180 : 150 154.
22. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J. Urol. 2002 167 : 1231 1234.
23. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 2002 167 : 1664 1669.
24. Kikuchi E, Nakashima J, Ishibashi M et al. Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer 2000 89 : 842 849.
25. Horinaga M, Nakashima J, Ishibashi M et al. Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: the usefulness of complexed prostate specific antigen adjusted for transition zone volume. J. Urol. 2002 168 : 986 990.
26. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 279 : 1542 1547.
27. Kawamura K, Suzuki H, Kamiya N et al. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Int. J. Urol. 2008 15 : 598 603.
28. Kawakami S, Koga F, Fujii Y et al. History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. Int. J. Urol. 2008 15 : 1055 1060.
29. Suzuki H, Komiya A, Kamiya N et al. Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 2006 67 : 131 136.